Amgen Stock Eases as Call Skew Fades Before Q3 Results

AMGN reports third-quarter results after the close on November 5, arriving with the stock down slightly from yesterday's close of $461.26, a retreat from the $465 level where it traded just 24 hours earlier, though still up nearly 3% on the week and 14% over the past month.

Options positioning has cooled from the pronounced call skew in yesterday's preview. The put/call ratio now reads 0.839, still below its 20-day average of 0.978, but the z-score has pulled back to roughly minus two, meaning the call-heavy tilt is there but less extreme than it appeared at Monday's open. That drift back toward neutral is consistent with the small pullback in the share price: some of the momentum that drove the bullish options flow has dissipated as the actual print approaches.

The Street is split on whether the stock's 42% year-to-date gain is justified. The optimistic case rests on six key growth products that rose 26% year on year in the second quarter, contributing nearly 70% of product sales, with Repatha, Uplizna, Tezspire, and Imdelltra still expanding across major markets and a pipeline that has delivered positive Phase 3 results in EoE, first-line ES-SCLC, and an autoimmune indication. The more cautious view, reflected in Guggenheim and Morgan Stanley both carrying below-market targets in the $359 to $378 range, points to Q3 revenue expectations of roughly $9.91 billion against consensus of $10.05 billion, softer script trends in Tavneos and Xgeva, and reduced olpasiran assumptions following negative readthroughs from an Lp(a) competitor. The mean analyst price target of $397 sits about 14% below Monday's close, a gap that has widened as the stock has run. Oppenheimer and UBS both hold targets above $460, so the debate is genuinely polarised rather than modestly shaded.

Short interest is not a central part of this story. At 2.4% of the free float, it has drifted up roughly 9% over the past month but remains well within normal bounds for a large-cap biotech. Borrow availability is effectively unlimited, and cost to borrow at 0.44% is negligible despite a sharp-looking 75% weekly rise from an extremely low base. The lending market carries no meaningful signal either way.

The print will test whether Amgen's commercial execution across its volume-driven growth products can close the gap between what the bulls are pricing in at current levels and the more cautious revenue and EPS estimates that sit comfortably below the Street consensus.